Download PDF
Am J Perinatol
DOI: 10.1055/s-0044-1786174
Original Article

The Association between Sickle Cell Disease and Postpartum Severe Maternal Morbidity

Natalie E. Poliektov
1   Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia
,
Danielle M. Vuncannon
1   Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia
,
Thoa K. Ha
1   Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia
,
Michael K. Lindsay
1   Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia
,
Suchitra Chandrasekaran
1   Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Objective To compare the risk of severe maternal morbidity (SMM) from the delivery admission to 42 days' postdischarge among persons with sickle cell disease (SCD) to those without SCD.

Study Design This retrospective cohort study included deliveries ≥20 weeks' gestation at an urban safety net hospital in Atlanta, GA from 2011 to 2019. The exposure was SCD diagnosis. The outcome was a composite of SMM from the delivery admission to 42 days' postdischarge. SMM indicators as defined by the Centers for Disease Control and Prevention were identified using the International Classification of Diseases, Ninth and Tenth Revisions (ICD-9/10) codes; transfusion of blood products and sickle cell crisis were excluded.

Results Of N = 17,354 delivery admissions, n = 92 (0.53%) had SCD. Persons with SCD versus without SCD had an increased risk of composite SMM (15.22 vs. 2.29%, p < 0.001), acute renal failure (6.52 vs. 0.71%, p < 0.001), acute respiratory distress syndrome (4.35 vs. 0.17%, p < 0.001), puerperal cerebrovascular disorders (3.26 vs. 0.10%, p < 0.001), sepsis (4.35 vs. 0.42%, p < 0.01), air and thrombotic embolism (5.43 vs. 0.10%, p < 0.001), and ventilation (2.17 vs. 0.09%, p < 0.01). Ultimately, those with SCD had an approximately 6-fold higher incidence risk ratio of SMM, which remained after adjustment for confounders (adjusted incidence risk ratio [aIRR]: 5.96, 95% confidence interval [CI]: 3.4–9.19, p < 0.001). Persons with SCD in active vaso-occlusive crisis at the delivery admission had an approximately 9-fold higher risk of SMM up to 42 days' postdischarge compared with those with SCD not in crisis at the delivery admission (incidence: 25.71 vs. 8.77%, p < 0.05; aIRR: 8.92, 95% CI: 4.5–10.04, p < 0.05). Among those with SCD, SMM at the delivery admission was primarily related to renal and cerebrovascular events, whereas most postpartum SMM was related to respiratory events or sepsis.

Conclusion SCD is significantly associated with an increased risk of SMM during the delivery admission and through 42 days' postdischarge. Active crisis at delivery further increases the risk of SMM.

Key Points

  • Sickle cell disease was associated with an approximately 6-fold increased risk of SMM.

  • Active vaso-occlusive crisis at delivery was associated with an approximately 9-fold increased risk of SMM.

  • 48% of SMM events in persons with SCD occurred postpartum and were respiratory- or sepsis-related.

Keywords

sickle cell disease - sickle cell crisis - severe maternal morbidity - composite maternal morbidity - pregnancy - delivery - postpartum

Supplementary Material



Publication History

Received: 20 February 2024

Accepted: 24 March 2024

Article published online:
23 April 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Bender MA. Sickle cell disease. In: Adam MP, Everman DB, Mirzaa GM. et al, eds. GeneReviews((R)). Seattle (WA); 1993
    Google Scholar
  • 2 Howard J, Oteng-Ntim E. The obstetric management of sickle cell disease. Best Pract Res Clin Obstet Gynaecol 2012; 26 (01) 25-36
    CrossrefPubMedGoogle Scholar
  • 3 Centers for Disease Control and Prevention. Data and statistics on sickle cell disease. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. Accessed July 6, 2023 at: https://www.cdc.gov/ncbddd/sicklecell/data.htm
    PubMedGoogle Scholar
  • 4 Lubeck D, Agodoa I, Bhakta N. et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open 2019; 2 (11) e1915374
    CrossrefPubMedGoogle Scholar
  • 5 Boga C, Ozdogu H. Pregnancy and sickle cell disease: a review of the current literature. Crit Rev Oncol Hematol 2016; 98: 364-374
    CrossrefPubMedGoogle Scholar
  • 6 Alayed N, Kezouh A, Oddy L, Abenhaim HA. Sickle cell disease and pregnancy outcomes: population-based study on 8.8 million births. J Perinat Med 2014; 42 (04) 487-492
    CrossrefPubMedGoogle Scholar
  • 7 Chou ST, Fasano RM. Management of patients with sickle cell disease using transfusion therapy: guidelines and complications. Hematol Oncol Clin North Am 2016; 30 (03) 591-608
    CrossrefPubMedGoogle Scholar
  • 8 Barfield WD, Barradas DT, Manning SE, Kotelchuck M, Shapiro-Mendoza CK. Sickle cell disease and pregnancy outcomes: women of African descent. Am J Prev Med 2010; 38 (4, suppl) S542-S549
    CrossrefPubMedGoogle Scholar
  • 9 Boafor TK, Olayemi E, Galadanci N. et al. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG 2016; 123 (05) 691-698
    CrossrefPubMedGoogle Scholar
  • 10 Boulet SL, Okoroh EM, Azonobi I, Grant A, Craig Hooper W. Sickle cell disease in pregnancy: maternal complications in a Medicaid-enrolled population. Matern Child Health J 2013; 17 (02) 200-207
    CrossrefPubMedGoogle Scholar
  • 11 Kuo K, Caughey AB. Contemporary outcomes of sickle cell disease in pregnancy. Am J Obstet Gynecol 2016; 215 (04) 505.e1-505.e5
    CrossrefPubMedGoogle Scholar
  • 12 Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol 2008; 199 (02) 125.e1-125.e5
    CrossrefPubMedGoogle Scholar
  • 13 Serjeant GR, Loy LL, Crowther M, Hambleton IR, Thame M. Outcome of pregnancy in homozygous sickle cell disease. Obstet Gynecol 2004; 103 (06) 1278-1285
    CrossrefPubMedGoogle Scholar
  • 14 Early ML, Eke AC, Gemmill A, Lanzkron S, Pecker LH. Severe maternal morbidity and mortality in sickle cell disease in the National Inpatient Sample, 2012–2018. JAMA Netw Open 2023; 6 (02) e2254552
    CrossrefPubMedGoogle Scholar
  • 15 Oteng-Ntim E. Pregnancy in women with sickle cell disease is associated with risk of maternal and perinatal mortality and severe morbidity. Evid Based Nurs 2017; 20 (02) 43
    CrossrefPubMedGoogle Scholar
  • 16 Bae E, Tangel V, Liu N, Abramovitz SE, White RS. Inpatient mortality and postpartum readmission rates in sickle cell disease pregnancies: a multistate analysis, 2007-2014. J Matern Fetal Neonatal Med 2021; 34 (17) 2783-2792
    CrossrefPubMedGoogle Scholar
  • 17 Centers for Disease Control and Prevention. Severe maternal morbidity in the United States. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion. Accessed July 3, 2023 at: https://www.cdc.gov/reproductivehealth/maternalinfanthealth/severematernalmorbidity.html
    PubMedGoogle Scholar
  • 18 Grobman WA, Bailit JL, Rice MM. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Frequency of and factors associated with severe maternal morbidity. Obstet Gynecol 2014; 123 (04) 804-810
    CrossrefPubMedGoogle Scholar
  • 19 Ha TK, Boulet SL, Cotsonis G, Geary F, Jamieson DJ, Lindsay M. Association of sickle cell disease with severe maternal morbidity. Obstet Gynecol 2023; 141 (01) 163-169
    CrossrefPubMedGoogle Scholar
  • 20 Chen J, Cox S, Kuklina EV, Ferre C, Barfield W, Li R. Assessment of incidence and factors associated with severe maternal morbidity after delivery discharge among women in the US. JAMA Netw Open 2021; 4 (02) e2036148
    CrossrefPubMedGoogle Scholar
  • 21 Petersen EE, Davis NL, Goodman D. et al. Vital signs: pregnancy-related deaths, United States, 2011–2015, and strategies for prevention, 13 states, 2013–2017. MMWR Morb Mortal Wkly Rep 2019; 68 (18) 423-429
    CrossrefPubMedGoogle Scholar
  • 22 Centers for Disease Control and Prevention. Pregnancy mortality surveillance system: trends in pregnancy-related deaths. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion. Accessed July 3, 2023 at: https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.htm
    PubMedGoogle Scholar
  • 23 Himes KP, Bodnar LM. Validation of criteria to identify severe maternal morbidity. Paediatr Perinat Epidemiol 2020; 34 (04) 408-415
    CrossrefPubMedGoogle Scholar
  • 24 Main EK, Abreo A, McNulty J. et al. Measuring severe maternal morbidity: validation of potential measures. Am J Obstet Gynecol 2016; 214 (05) 643.e1-643.e10
    CrossrefPubMedGoogle Scholar
  • 25 Shet AS, Lizarralde-Iragorri MA, Naik RP. The molecular basis for the prothrombotic state in sickle cell disease. Haematologica 2020; 105 (10) 2368-2379
    CrossrefPubMedGoogle Scholar
  • 26 Smith-Whitley K. Complications in pregnant women with sickle cell disease. Hematology (Am Soc Hematol Educ Program) 2019; 2019 (01) 359-366
    CrossrefPubMedGoogle Scholar
  • 27 Boulet SL, Stanhope KK, Worrell N, Jamieson DJ. Risk of recurrent severe maternal morbidity in an urban safety-net health system. Am J Obstet Gynecol MFM 2022; 4 (02) 100568
    CrossrefPubMedGoogle Scholar
  • 28 Platt OS, Brambilla DJ, Rosse WF. et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330 (23) 1639-1644
    CrossrefPubMedGoogle Scholar
  • 29 Kilpatrick SK, Ecker JL. American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine. Severe maternal morbidity: screening and review. Am J Obstet Gynecol 2016; 215 (03) B17-B22
    CrossrefPubMedGoogle Scholar
  • 30 Sun PM, Wilburn W, Raynor BD, Jamieson D. Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet Gynecol 2001; 184 (06) 1127-1130
    CrossrefPubMedGoogle Scholar
  • 31 Metcalfe A, Sheikh M, Hetherington E. Impact of the ICD-9-CM to ICD-10-CM transition on the incidence of severe maternal morbidity among delivery hospitalizations in the United States. Am J Obstet Gynecol 2021; 225 (04) 422.e1-422.e11
    CrossrefPubMedGoogle Scholar
  • 32 Stanhope KK, Joseph NT, Platner M. et al. Validation of ICD-10 codes for gestational and pregestational diabetes during pregnancy in a large, public hospital. Epidemiology 2021; 32 (02) 277-281
    CrossrefPubMedGoogle Scholar